Regulatory
-
According to Circassia Pharmaceuticals, the UK has approved the company’s generic fluticasone propionate MDI for the treatment of asthma under the European decentralized procedure. The MAA includes the same three strengths (50µg, 125µg and 250µg… Read more . . .
-
The FDA has approved Adapt Pharma’s Narcan naloxone nasal spray for the treatment of opioid overdoses less than four months after the submission of the company’s NDA. Lightlake Therapeutics licensed the intranasal naloxone to Adapt… Read more . . .
-
Novartis has announced FDA approval for the Seebri Neohaler glycopyrrolate DPI and the Utibron Neohaler indacaterol/glycopyrrolate DPI for the treatment of COPD. According to the company, both inhalers should be available in the first quarter… Read more . . .
-
Meda Pharmaceuticals in Canada has announced that Health Canada has approved Dymista azelastine hydrochloride/fluticasone propionate nasal spray for the treatment of moderate-to-severe seasonal allergic rhinitis for patients age 12 years old and older who do… Read more . . .
-
Adapt Pharma announced that the FDA has accepted its filing and granted priority review to its New Drug Application for Narcan naloxone hydrochloride nasal spray for the treatment of opioid overdose. Adapt submitted the NDA… Read more . . .
-
GlaxoSmithKline and Theravance have announced plans to file a supplemental Japanese New Drug Application for the Relvar/Breo Ellipta fluticasone furoate/vilanterol DPI for the treatment of COPD in the first quarter of 2016. The Japanese MHLW… Read more . . .
-
Boehringer Ingelheim’s Spiriva Respimat tiotropium soft mist inhaler has now been approved by the FDA for the treatment of asthma in patients 12 years old and older. Spiriva Respimat was approved for the treatment of… Read more . . .
-
Teva has announced the FDA’s acceptance of a supplemental new drug application (sNDA) for the ProAir RespiClick albuterol DPI for the treatment of asthma in patients aged 4 to 11. The FDA approved ProAir RespiClick… Read more . . .
-
According to Serendex Pharmaceuticals, German regulators have cleared the way for the company to initiate a phase 2 clinical trial of inhaled molgramostim (Molgradex) for the treatment of pneumonia-associated acute respiratory distress syndrome (ARDS). Earlier… Read more . . .
-
GSK and Theravance, Inc. have announced that the Breo Ellipta fluticasone furoate/vilanterol DPI has been approved in Canada in 100/25 mcg and 200/25 mcg versions for the treatment of asthma in patients aged 18 years… Read more . . .
Upcoming Events
Sponsored by Intertek
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
October 21-October 22: MVIC Symposium, Lund, Sweden
November 10-November 11: Rescon Europe 2026, Porto, Portugal
December 9-December 11: DDL 2026, Edinburgh, Scotland